{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:32:11Z","timestamp":1784752331707,"version":"3.55.0"},"reference-count":177,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T00:00:00Z","timestamp":1708214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chemoimmunotherapy and cellular therapy are the mainstay of the treatment of relapsed\/refractory (R\/R) lymphomas. Development of resistance and commonly encountered toxicities of these treatments limit their role in achieving desired response rates and durable remissions. The Antibody\u2013Drug Conjugate (ADC) is a novel class of targeted therapy that has demonstrated significant efficacy in treating various cancers, including lymphomas. To date, three ADC agents have been approved for different lymphomas, marking a significant advancement in the field. In this article, we aim to review the concept of ADCs and their application in lymphoma treatment, provide an analysis of currently approved agents, and discuss the ongoing advancements of ADC development.<\/jats:p>","DOI":"10.3390\/cancers16040827","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T11:50:07Z","timestamp":1708429807000},"page":"827","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma"],"prefix":"10.3390","volume":"16","author":[{"given":"Ali","family":"Al Sbihi","sequence":"first","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-2422","authenticated-orcid":false,"given":"Maryam","family":"Alasfour","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-8682","authenticated-orcid":false,"given":"Georgios","family":"Pongas","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,18]]},"reference":[{"key":"ref_1","unstructured":"Jamil, A., and Mukkamalla, S.K.R. (2023). Lymphoma, StatPearls."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Thandra, K.C., Barsouk, A., Saginala, K., Padala, S.A., Barsouk, A., and Rawla, P. (2021). Epidemiology of Non-Hodgkin\u2019s Lymphoma. Med. Sci., 9.","DOI":"10.3390\/medsci9010005"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/10428194.2018.1473576","article-title":"Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: A multi-center retrospective analysis of consecutively treated patients in the real world","volume":"60","author":"Manna","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","article-title":"Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","volume":"28","author":"Corradini","year":"2014","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41375-021-01285-3","article-title":"Treatment resistance in diffuse large B-cell lymphoma","volume":"35","author":"He","year":"2021","journal-title":"Leukemia"},{"key":"ref_6","first-page":"103","article-title":"Long-term toxicity of chemotherapy and radiotherapy in lymphoma survivors: Optimizing treatment for individual patients","volume":"13","author":"Hodgson","year":"2015","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/onco.13915","article-title":"Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma","volume":"26","author":"Johnson","year":"2021","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Klener, P., and Klanova, M. (2020). Drug Resistance in Non-Hodgkin Lymphomas. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062081"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/leu.2012.81","article-title":"Mast cells promote the growth of Hodgkin\u2019s lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib","volume":"26","author":"Mizuno","year":"2012","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/path.5043","article-title":"Novel insights into the disease dynamics of B-cell lymphomas in the Genomics Era","volume":"244","author":"Chan","year":"2018","journal-title":"J. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, Present, and Future of Rituximab-The World\u2019s First Oncology Monoclonal Antibody Therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1124\/pr.114.009373","article-title":"Antibody Drug Conjugates for Cancer Therapy","volume":"68","author":"Polakis","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/PPO.0000000000000631","article-title":"Evolving Landscape of Antibody Drug Conjugates in Lymphoma","volume":"28","author":"Prakash","year":"2022","journal-title":"Cancer J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/annonc\/mdw424","article-title":"Antibody drug conjugates: Lessons from 20 years of clinical experience","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/14712598.2021.1880562","article-title":"What makes a good antibody-drug conjugate?","volume":"21","author":"Galbraith","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lucas, A.T., Price, L.S.L., Schorzman, A.N., Storrie, M., Piscitelli, J.A., Razo, J., and Zamboni, W.C. (2018). Factors Affecting the Pharmacology of Antibody-Drug Conjugates. Antibodies, 7.","DOI":"10.3390\/antib7010010"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","article-title":"Antibody-drug conjugates: Current status and future directions","volume":"19","author":"Perez","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4161\/mabs.2.3.11788","article-title":"Stability of IgG isotypes in serum","volume":"2","author":"Correia","year":"2010","journal-title":"mAbs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1208\/s12248-014-9684-6","article-title":"Immunogenicity of antibody drug conjugates: Bioanalytical methods and monitoring strategy for a novel therapeutic modality","volume":"17","author":"Hock","year":"2015","journal-title":"AAPS J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC Linker Chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes","volume":"234","author":"Lotfinia","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2165\/00003495-200161090-00007","article-title":"Gemtuzumab ozogamicin","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19420862.2015.1114320","article-title":"The INNs and outs of antibody nonproprietary names","volume":"8","author":"Jones","year":"2016","journal-title":"MAbs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-Drug Conjugates: A Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/med.21568","article-title":"Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy","volume":"39","author":"Arnst","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Waight, A.B., Bargsten, K., Doronina, S., Steinmetz, M.O., Sussman, D., and Prota, A.E. (2016). Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160890"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-62703-541-5_4","article-title":"Antibody-drug conjugate payloads","volume":"1045","author":"Anderl","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1158\/1078-0432.CCR-21-1353","article-title":"Unmasking New Promises: Expanding the Antigen Landscape For Antibody-Drug Conjugates","volume":"27","author":"Oberoi","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy","volume":"235","author":"Yaghoubi","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.bmcl.2016.03.032","article-title":"Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity","volume":"26","author":"Hennessy","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","article-title":"HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells","volume":"20","author":"Ko","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"104429","DOI":"10.1016\/j.yrtph.2019.104429","article-title":"An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates","volume":"107","author":"Saber","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1158\/1535-7163.MCT-16-0343","article-title":"Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates","volume":"16","author":"Burke","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hafeez, U., Parakh, S., Gan, H.K., and Scott, A.M. (2020). Antibody-Drug Conjugates for Cancer Therapy. Molecules, 25.","DOI":"10.3390\/molecules25204764"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1535-7163.MCT-16-0641","article-title":"Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers","volume":"16","author":"Pillow","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1158\/1535-7163.MCT-16-0184","article-title":"A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity","volume":"15","author":"Miller","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/1535-7163.MCT-17-0940","article-title":"A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs)","volume":"17","author":"Miller","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: Recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Amouzegar, A., Chelvanambi, M., Filderman, J.N., Storkus, W.J., and Luke, J.J. (2021). STING Agonists as Cancer Therapeutics. Cancers, 13.","DOI":"10.3390\/cancers13112695"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"Ramanjulu","year":"2018","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1199152","DOI":"10.3389\/fphar.2023.1199152","article-title":"Targeting the stimulator of interferon genes (STING) in breast cancer","volume":"14","author":"Ma","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3389\/fphar.2018.00878","article-title":"The Role of Toll-Like Receptor in Inflammation and Tumor Immunity","volume":"9","author":"Cen","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e1526250","DOI":"10.1080\/2162402X.2018.1526250","article-title":"Trial Watch: Toll-like receptor agonists in cancer immunotherapy","volume":"7","author":"Smith","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_51","first-page":"A361","article-title":"605\u2005Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models","volume":"8","author":"LeBlanc","year":"2020","journal-title":"J. Immuno Ther. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1039\/C6MD00347H","article-title":"Small molecule-mediated protein knockdown as a new approach to drug discovery","volume":"7","author":"Tinworth","year":"2016","journal-title":"MedChemComm"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1039\/D2CS00141A","article-title":"Degrader-antibody conjugates","volume":"51","author":"Dragovich","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1021\/acs.bioconjchem.3c00366","article-title":"Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine\/Threonine-Protein Kinase 2 in HER2+ Cell Lines","volume":"34","author":"Chan","year":"2023","journal-title":"Bioconjug Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Lu, J., Jiang, F., Lu, A., and Zhang, G. (2016). Linkers Having a Crucial Role in Antibody-Drug Conjugates. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17040561"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1021\/bc00005a005","article-title":"Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers","volume":"1","author":"Mueller","year":"1990","journal-title":"Bioconjugate Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1039\/C6SC01831A","article-title":"Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates","volume":"8","author":"Pillow","year":"2017","journal-title":"Chem. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: Recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: Recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-021-01097-z","article-title":"Antibody-drug conjugates for the treatment of lymphoma: Clinical advances and latest progress","volume":"14","author":"Chu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"763","DOI":"10.37349\/etat.2022.00112","article-title":"Antibody-drug conjugates for lymphoma patients: Preclinical and clinical evidences","volume":"3","author":"Barreca","year":"2022","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"Dhimolea","year":"2012","journal-title":"mAbs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3109\/10428194.2011.574761","article-title":"CD30: An important new target in hematologic malignancies","volume":"52","author":"Deutsch","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5045\/kjh.2012.47.1.8","article-title":"Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation","volume":"47","author":"Currin","year":"2012","journal-title":"Korean J. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions","volume":"7","author":"Pileri","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-136422","article-title":"SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma","volume":"136","author":"Herrera","year":"2020","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","article-title":"U.S. Food and Drug Administration approval summary: Brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma","volume":"18","author":"McGinn","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"ref_78","first-page":"2075","article-title":"Nivolumab and brentuximab vedotin with or without bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults","volume":"141","author":"Leblanc","year":"2023","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: High correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: Final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","article-title":"Antibody-drug conjugates for the treatment of non-Hodgkin\u2019s lymphoma: Target and linker-drug selection","volume":"69","author":"Polson","year":"2009","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","article-title":"B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"52","author":"Young","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_87","first-page":"2721","article-title":"Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma","volume":"114","author":"Dornan","year":"2009","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/17512433.2020.1826303","article-title":"Antibody-drug conjugates for previously treated aggressive lymphomas: Focus on polatuzumab vedotin","volume":"13","author":"Burke","year":"2020","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Sawalha, Y. (2021). Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies. J. Pers. Med., 11.","DOI":"10.3390\/jpm11121345"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_91","unstructured":"Center for Drug Evaluation and Research (No Date) FDA Approves Polatuzumab Vedotin-Piiq for Previously Untreated Diffuse, U.S (2024, January 20). Food and Drug Administration, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-polatuzumab-vedotin-piiq-previously-untreated-diffuse-large-b-cell-lymphoma-not."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e91359ec","DOI":"10.1097\/01.HS9.0000967820.91359.ec","article-title":"S227: Initial safety data from the phase 3 polar bear trial in elderly or frail patients with diffuse large cell lymphoma, comparing r-pola-mini-chp andr-mini-chop","volume":"7","author":"Jerkeman","year":"2023","journal-title":"HemaSphere"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: A phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1016\/S2352-3026(21)00311-2","article-title":"Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: A cohort of a multicentre, single-arm, phase 1b\/2 study","volume":"8","author":"Diefenbach","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2022-157720","article-title":"A Phase Ib\/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed\/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update","volume":"140","author":"Diefenbach","year":"2022","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed\/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib\/II Study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","article-title":"CD19: A promising B cell target for rheumatoid arthritis","volume":"5","author":"Tedder","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: A biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1182\/blood-2019-129600","article-title":"Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies","volume":"134","author":"Horna","year":"2019","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"ref_102","unstructured":"Krishna Goparaju, A.W. (2024, January 20). The Anti-cd19 Antibody\u2013Drug Conjugate Loncastuximab Tesirine, Touchoncology. Available online: https:\/\/touchoncology.com\/lymphoma\/journal-articles\/the-anti-cd19-antibody-drug-conjugate-loncastuximab-tesirine."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","article-title":"A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma","volume":"25","author":"Kahl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_105","unstructured":"Center for Drug Evaluation and Research (no date b) FDA Grants Accelerated Approval, U.S (2024, January 20). Food and Drug Administration, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-loncastuximab-tesirine-lpyl-large-b-cell-lymphoma."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/blood-2023-178825","article-title":"Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed\/Refractory Follicular Lymphoma\u2014A Phase 2 Study","volume":"142","author":"Alderuccio","year":"2023","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-140384","article-title":"A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma","volume":"136","author":"Reagan","year":"2020","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e4008899","DOI":"10.1097\/01.HS9.0000971416.40088.99","article-title":"P1130: Frontline brentuximab vedotin and CHP (A+CHP) in patients with peripheral T-cell lymphoma with less than 10% CD30 expression: Initial safety and efficacy results from the phase 2 study SGN35-032","volume":"7","author":"Iyer","year":"2023","journal-title":"HemaSphere"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: A single centre, phase 1\/2 study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-138849","article-title":"A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma","volume":"136","author":"Barta","year":"2020","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Bannerji, R., Yuen, S., Phillips, T., Arthur, C., Isufi, I., Marlton, P., Seymour, J.F., Corradini, P., Molinari, A., and Gritti, G. (2021). Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL): Primary analysis of a phase 1B\/2 trial. Hematol. Oncol., 39.","DOI":"10.1002\/hon.23_2880"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-136361","article-title":"Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib\/II Study","volume":"136","author":"Gritti","year":"2020","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/01.HS9.0000847620.60858.05","article-title":"P1189: Initial safety run-in results of the phase iii polargo trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients with relapsed\/refractory DIFFUSE LARGE B-CELL lymphoma","volume":"6","author":"McMillan","year":"2022","journal-title":"HemaSphere"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2022-165699","article-title":"Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"140","author":"Herrera","year":"2022","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-135835","article-title":"Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed\/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel","volume":"136","author":"Strati","year":"2020","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2021-147765","article-title":"Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3)","volume":"138","author":"Zinzani","year":"2021","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Depaus, J., Wagner-Johnston, N., Zinzani, P.L., Phillips, T.J., Maly, J., Ferrari, S., Bachy, E., Bryan, L.J., Delwail, V., and Janakiram, M. (2021). Clinical activity of loncastuximab tesirine plus ibrutinib in non-hodgkin lymphoma: Updated lotis 3 phase 1 results. Hematol. Oncol., 39.","DOI":"10.1002\/hon.150_2880"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1016\/S2152-2650(23)01332-0","article-title":"ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R\/R DLBCL","volume":"23","author":"Kwiatek","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Carlo-Stella, C., Depaus, J., Hess, B.T., Kingsley, E., Zinzani, P.L., Ungar, D., Dai, V., Wang, L., and Ardeshna, K.M. (2021). A phase 2 randomized study of loncastuximab tesirine (lonca) versus (vs) idelalisib in patients (pts) with relapsed or refractory (r\/r) follicular lymphoma (fl)\u2013lotis-6. Hematol. Oncol., 39.","DOI":"10.1002\/hon.176_2880"},{"key":"ref_121","unstructured":"Clinicaltrials.gov (2024, January 20). Available online: https:\/\/clinicaltrials.gov\/study\/NCT04998669."},{"key":"ref_122","unstructured":"Clinicaltrials.gov (2024, January 20). Available online: https:\/\/clinicaltrials.gov\/study\/NCT05053659."},{"key":"ref_123","unstructured":"Clinicaltrials.gov (2024, January 20). Available online: https:\/\/clinicaltrials.gov\/study\/NCT04974996."},{"key":"ref_124","unstructured":"Clinicaltrials.gov (2024, January 20). Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT05144009."},{"key":"ref_125","unstructured":"Clinicaltrials.gov (2024, January 20). Available online: https:\/\/clinicaltrials.gov\/study\/NCT05249959."},{"key":"ref_126","unstructured":"Clinicaltrials.gov (2024, January 20). Available online: https:\/\/clinicaltrials.gov\/study\/NCT04970901."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1182\/blood-2022-163277","article-title":"A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R\/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)","volume":"140","author":"Hess","year":"2022","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2019-128036","article-title":"Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"ref_129","unstructured":"Clinicaltrials.gov (2024, January 20). Available online: https:\/\/clinicaltrials.gov\/study\/NCT05190705."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1021\/acs.molpharmaceut.5b00175","article-title":"Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation","volume":"12","author":"Hong","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk. Lymphoma"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/jco.2014.32.15_suppl.8506","article-title":"Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL.; NCT01472887)","volume":"32","author":"Trneny","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjh.13992","article-title":"A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"173","author":"Coiffier","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_134","unstructured":"Denintuzumab Mafodotin, National Center for Biotechnology Information (2024, January 20). PubChem Compound Database, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Denintuzumab-mafodotin."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood.V126.23.1328.1328","article-title":"A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma","volume":"126","author":"Fathi","year":"2015","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V126.23.182.182","article-title":"A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed\/Refactory B-Lineage Non-Hodgkin Lymphoma","volume":"126","author":"Moskowitz","year":"2015","journal-title":"Blood"},{"key":"ref_137","unstructured":"Clinicaltrials.gov (2024, January 20). Available online: https:\/\/clinicaltrials.gov\/study\/NCT02592876."},{"key":"ref_138","unstructured":"Clinicaltrials.gov (2024, January 20). Available online: https:\/\/clinicaltrials.gov\/study\/NCT02855359."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40259-013-0016-7","article-title":"Targeting CD22 in B-cell malignancies: Current status and clinical outlook","volume":"27","author":"Tuscano","year":"2013","journal-title":"BioDrugs"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: Results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.14094","article-title":"A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy","volume":"174","author":"Goy","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/1535-7163.MCT-12-1173","article-title":"DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma","volume":"12","author":"Li","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-16-0772","article-title":"Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with\/without Rituximab in Patients with Relapsed\/Refractory B-cell Non-Hodgkin Lymphoma","volume":"23","author":"Advani","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: Final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Gorczyca, W. (2010). Flow Cytometry in Neoplastic Hematology: Morphologic\u2014Immunophenotypic Correlation, CRC Press. [2nd ed.].","DOI":"10.3109\/9781841847443"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/hon.134_2630","article-title":"The ANTI-Cd25 antibody-drug conjugate camidanlumab tesirine (ADCT-301) presents a strong preclinical activity both as single agent and in combination in lymphoma cell lines","volume":"37","author":"Spriano","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: A phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/blood-2016-11-748137","article-title":"Staining the target: CD37 expression in lymphomas","volume":"128","author":"Bertoni","year":"2016","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood.V128.22.4187.4187","article-title":"Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529","volume":"128","author":"Gaudio","year":"2016","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10637-018-0570-4","article-title":"Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: A dose-escalation, phase I study","volume":"36","author":"Stathis","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2021-145102","article-title":"Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin\u2019S B-Cell Lymphomas\u2014A Phase 2 Study","volume":"138","author":"Levy","year":"2021","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: The new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/1078-0432.CCR-08-0916","article-title":"Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker","volume":"14","author":"Oflazoglu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","article-title":"Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma","volume":"32","author":"Tannir","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1158\/1538-7445.AM2017-4589","article-title":"Abstract 4589: Preclinical investigation of SGN-CD70A antibody-drug conjugate in T cell lymphomas","volume":"77","author":"Yang","year":"2017","journal-title":"Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma","volume":"37","author":"Phillips","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-021-01143-w","article-title":"The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"EVIDoa2100001","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers","volume":"1","author":"Wang","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1200\/JCO.2023.41.16_suppl.7531","article-title":"Zilovertamab vedotin (MK 2140) in relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study","volume":"41","author":"Ozcan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_161","unstructured":"Clinicaltrials.gov (2024, January 20). Available online: https:\/\/clinicaltrials.gov\/study\/NCT05406401."},{"key":"ref_162","unstructured":"Clinicaltrials.gov (2024, January 20). Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05139017."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_164","unstructured":"Clinicaltrials.gov (2024, January 20). Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT03088878."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/blood-2023-182400","article-title":"SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas","volume":"142","author":"Hamblett","year":"2023","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1182\/blood-2022-158983","article-title":"IKS03, a Next Generation CD19-Targeted Antibody Drug Conjugate, Shows Potent Activity in Preclinical Models of Aggressive B-Cell Lymphomas","volume":"140","author":"Deckert","year":"2022","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2023-174064","article-title":"IKS03, a Novel CD19-Targeted Antibody Drug Conjugate, Induces Target Dependent In Vivo Cell Killing of B-Cell Lymphoma Xenografts By DNA Crosslinking","volume":"142","author":"Deckert","year":"2023","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Wang, B., Wang, M., Ao, D., and Wei, X. (2022). CXCL13-CXCR5 axis: Regulation in inflammatory diseases and cancer. Biochim. Biophys. Acta Rev. Cancer, 1877.","DOI":"10.1016\/j.bbcan.2022.188799"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2023-182185","article-title":"Comparison of the CXCR5-Antibody Drug Conjugate (ADC.; VIP924) to a CD19-ADC and a CD79b-ADC in a Humanized Rec-1 Mantle Cell Lymphoma (MCL) Mouse Model","volume":"142","author":"Schomber","year":"2023","journal-title":"Blood"},{"key":"ref_170","unstructured":"Challener, C.A. (2024, January 20). Optimization of Linker Chemistries for Antibody-Drug Conjugates. BioPharm International. 30 October 2023. Available online: https:\/\/www.biopharminternational.com\/view\/optimization-of-linker-chemistries-for-antibody-drug-conjugates."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.7150\/thno.62444","article-title":"Synthesis of precision antibody conjugates using proximity-induced chemistry","volume":"11","author":"Cao","year":"2021","journal-title":"Theranostics"},{"key":"ref_173","unstructured":"Conjugate Development Services|Bioconjugates & ADCs (2024, January 20). Abzena. 23 November 2023. Available online: https:\/\/abzena.com\/capabilities\/bioconjugates-and-chemistry\/bioconjugates-adcs\/."},{"key":"ref_174","first-page":"728","article-title":"AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production","volume":"34","author":"Fujii","year":"2023","journal-title":"Bioconjug Chem."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e202204706","DOI":"10.1002\/slct.202204706","article-title":"Tag-Free Antibody Modification Mediated by Lipoic Acid Ligase A: Application to Antibody-Drug Conjugates Production","volume":"8","author":"Yamazaki","year":"2023","journal-title":"ChemistrySelect"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1535-7163.MCT-21-0009","article-title":"A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade","volume":"20","author":"DaSilva","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Schwach, J., Abdellatif, M., and Stengl, A. (2022). More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates. Front. Biosci., 27.","DOI":"10.31083\/j.fbl2708240"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/827\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:01:47Z","timestamp":1760104907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,18]]},"references-count":177,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["cancers16040827"],"URL":"https:\/\/doi.org\/10.3390\/cancers16040827","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,18]]}}}